CryoLife Revenue and Competitors

CryoLife, Inc., The leader in transplant preservation, surgical adhesives and tissue engineered implantable devices makes an overwhelming commitment to the wellness and spirit of people of the world by providing state of the art implantable devices for patientsFounded in 1984, CryoLife was the first biomedical company to specialize in the low temperature preservation of human heart valves used for complex cardiac reconstruction primarily in children born with heart defects. Since those initial efforts, CryoLife’s preservation technology has expanded to include cardiac patches, saphenous veins, femoral arteries and veins as well as aorto-illiac vessels for use in central and peripheral vascular reconstruction. CryoLife’s proprietary processes for preserving these cardiovascular tissues have dramatically improved and enhanced the lives of one hundred thousand patients primarily in North America. Founded in 1984, CryoLife was the first biomedical company to specialize in the low temperature preservation of human heart valves used for complex cardiac reconstruction primarily in children born with heart defects. Since those initial efforts, CryoLife’s preservation technology has expanded to include cardiac patches, saphenous veins, femoral arteries and veins as well as aorto-illiac vessels for use in central and peripheral vascular reconstruction. CryoLife’s proprietary processes for preserving these cardiovascular tissues have dramatically improved and enhanced the lives of one hundred thousand patients primarily in North America. With studies beginning in 1991, Steven Goldstein, Ph.D., CryoLife’s Senior Director of Tissue Technologies, pushed the company into the forefront of a new approach in implantable tissue-based devices with the development of a decellularization technology that became known as the SynerGraft® process The SynerGraft process is designed to remove cells and antigens from the implantable tissues while preserving the integrity of the tissues’ collagen matrix. SynerGraft processed human pulmonary heart valves were cleared by the FDA in May of 2008 and SynerGraft processed pulmonary cardiac patch tissue was cleared by the FDA in August 2009. SynerGraft processed cardiac patches and valves are used by surgeons for complex cardiac reconstruction and valve replacement procedures.